CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares of Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $74.54, for a total value of $74,540.00. Following the sale, the director owned 1,000 shares in the company, valued at $74,540. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

CG Oncology Price Performance

CGON stock traded down $0.82 during mid-day trading on Tuesday, reaching $76.29. The company had a trading volume of 562,498 shares, compared to its average volume of 1,142,577. The stock has a 50 day simple moving average of $69.60 and a two-hundred day simple moving average of $64.91. The company has a market capitalization of $6.76 billion, a price-to-earnings ratio of -28.36 and a beta of 0.23. CG Oncology, Inc. has a 52 week low of $24.85 and a 52 week high of $79.39.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%.The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. On average, equities analysts predict that CG Oncology, Inc. will post -3.25 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on CGON. Wedbush upped their price target on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a research report on Wednesday, July 29th. Wall Street Zen lowered shares of CG Oncology from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Royal Bank Of Canada dropped their target price on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Finally, Wolfe Research started coverage on shares of CG Oncology in a research note on Tuesday, May 19th. They issued a “peer perform” rating for the company. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and an average price target of $83.18.

Institutional Investors Weigh In On CG Oncology

Large investors have recently added to or reduced their stakes in the business. Fiduciary Financial Advisors acquired a new stake in CG Oncology during the 2nd quarter valued at $28,000. NFSG Corp acquired a new position in shares of CG Oncology in the first quarter valued at $34,000. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CG Oncology in the fourth quarter valued at about $27,000. Comerica Bank raised its position in shares of CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Finally, Fifth Third Bancorp acquired a new stake in shares of CG Oncology during the 1st quarter worth about $74,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.